We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nondepleting Antibody Therapy Reverses Diabetes Symptoms in Mouse Model

By LabMedica International staff writers
Posted on 16 Jul 2012
A mouse diabetes model was treated by an immunotherapeutic approach based on novel nondepleting antibodies specific for the T-cell receptors CD4 and CD8.

Residual beta cells found at the time of the clinical onset of type I diabetes are sufficient to control hyperglycemia, if they can be rescued from ongoing autoimmune destruction. More...
To achieve this end, investigators at the University of North Carolina (Chapel Hill, NC, USA) developed an immunotherapeutic approach based on antibodies specific for the CD4 and CD8 receptors found on "autoreactive" T-cells. They then used these antibodies to treat members of a population of the mouse NOD diabetes model.

They reported in the June 29, 2012, online edition of the journal Diabetes that a short course of treatment with nondepleting antibodies specific for the CD4 and CD8 coreceptors rapidly reversed clinical disease in recent-onset diabetic NOD mice. Blood sugar levels returned to normal within 48 hours of treatment. Within five days, about 80% percent of the treated animals had entered diabetes remission with reversal of clinical symptoms.

Once established, remission was maintained indefinitely while immunity to foreign antigens was unimpaired. Induction of remission involved selective T-cell purging of the pancreas and draining pancreatic lymph nodes and upregulation of transforming growth factor (TGF)-beta1 by pancreas-resident antigen-presenting cells. Neutralization of TGF-beta1 blocked the induction of the remission process. In contrast, maintenance of remission was associated with tissue-specific immunoregulatory T cells.

"The protective effect is very rapid, and once established, is long-term," said senior author Dr. Roland Tisch, professor of microbiology and immunology at the University of North Carolina. "We followed the animals in excess of 400 days after the two antibody treatments, and the majority remained free of diabetes. And although the antibodies are cleared from within the animals in two to three weeks after treatment, the protective effect persists."

"We have demonstrated that the use of nondepleting antibodies is very robust," said Dr. Tisch. "We are now generating and plan to test antibodies that are specific for the human version of the CD4 and CD8 molecules."

Related Links:

University of North Carolina School



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.